ASH 2016 | Summary of CLL trials presented at ASH 2016
Stephan Stilgenbauer, MD, PhD of Ulm University, Ulm, Germany summarizes key trials on chronic lymphocytic leukemia (CLL) presented at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. Prof. Stilgenbauer explains that positive trials after chemoimmunotherapy with maintenance treatment (lenalidomide), in the frontline and the relapsed/refractory setting were presented. He also outlines the long-term follow-ups of single agent trials on ibrutinib, venetoclax and idelalisib and discusses new developments with agents that have not been licensed to date, such as BGB-3111 and acalabrutinib.
Get great new content delivered to your inboxSign up